An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common second-line chemotherapy regimens in patients ...
At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of drugs used to treat type 2 diabetes and, in some cases, obesity. GLP-1 RAs are very effective at lowering blood sugar levels. As an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results